Tharimmune, Inc. is a clinical-stage biotechnology company developing therapeutic candidates for inflammation and immunology, with its lead asset, TH104, targeting chronic pruritus in primary biliary cholangitis, a rare liver disease. The company is also advancing a pipeline of multi-specific antibodies aimed at validated targets in solid tumors, including PD-1, HER2, and HER3.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic pruritus, or uncontrollable itching, in primary biliary cholangitis (PBC) is a debilitating condition with limited effective treatments. Current therapeutic options often fail to provide adequate relief, significantly impacting the quality of life for patients with this rare liver disease. Additionally, many solid tumors express validated targets such as PD-1, HER2, and HER3, but effective multi-specific antibody therapies remain an unmet need.
Solution
Tharimmune is developing a portfolio of therapeutic candidates focused on inflammation, immunology, and oncology. Their lead clinical-stage asset, TH104, is designed to suppress chronic pruritus in PBC. Tharimmune is also advancing multi-specific antibodies that target unique epitopes on validated solid tumor targets, including PD-1, HER2, and HER3, using their proprietary EpiClick™ Technology. These antibodies are designed to offer novel mechanisms of action compared to existing therapies.
Target Audience
The primary target audiences include patients suffering from chronic pruritus associated with PBC, as well as individuals with solid tumors expressing PD-1, HER2, and HER3 targets.
Features
- TH104: A clinical-stage asset targeting chronic pruritus in primary biliary cholangitis (PBC)
- HSB-3215: anti-HER2/HER3 bispecific antibody targeting unique functional epitopes of HER2 and HER3
- HSB-0059: Bispecific Antibody Drug Conjugate (ADC) targeting novel epitopes on HER2 while blocking natural ligands to HER3 and/or preventing heterodimer formation
- HSB-1940: Anti-PD-1 Picobody™ Quatramer designed to target novel epitopes with greater binding affinity than approved biologics
- EpiClick™ Technology: A platform for developing multi-specific biologics that target unique epitopes on validated solid tumor targets